Literature DB >> 29589051

[Chemotherapy-induced nausea and vomiting : Current recommendations for prophylaxis].

E Storz1, J E Gschwend2, M Retz2.   

Abstract

The chemotherapy-induced nausea and vomiting (CINV) is one of the most frequent side effects in cytostatic therapy and a profound challenge during the therapy of cancer patients. Therefore, standardized guideline-orientated prophylaxis is essential and a fundamental contribution for the success of treatment. This review summarizes the current recommendations for CINV of the Multinational Association of Supportive Care in Cancer (MASCC) and European Society of Medical Oncology (ESMO), the American Society for Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN) and the S3-guideline Supportive Therapie of the Leitlinienprogramm Onkologie and shall facilitate its use in the daily routine.

Entities:  

Keywords:  Antiemetics; Cytostatics; Emetogenicity; Glucocorticoids; Guidelines

Mesh：

Substances：

Year:  2018        PMID： 29589051     DOI： 10.1007/s00120-018-0606-6

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  39 in total

1.  Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.

Authors:  R J Gralla; D Osoba; M G Kris; P Kirkbride; P J Hesketh; L W Chinnery; R Clark-Snow; D P Gill; S Groshen; S Grunberg; J M Koeller; G R Morrow; E A Perez; J H Silber; D G Pfister
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

Review 2.  Olanzapine for nausea and vomiting.

Authors:  Nerissa Licup
Journal:  Am J Hosp Palliat Care       Date:  2010-05-27       Impact factor: 2.500

Review 3.  International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice.

Authors:  Karin Jordan; Richard Gralla; Franziska Jahn; Alex Molassiotis
Journal:  Eur J Pharmacol       Date:  2013-10-21       Impact factor: 4.432

Review 4.  Anticipatory nausea and vomiting.

Authors:  Matti S Aapro; Alexander Molassiotis; Ian Olver
Journal:  Support Care Cancer       Date:  2004-12-15       Impact factor: 3.603

Review 5.  Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.

Authors:  Paul J Hesketh; Mark G Kris; Ethan Basch; Kari Bohlke; Sally Y Barbour; Rebecca Anne Clark-Snow; Michael A Danso; Kristopher Dennis; L Lee Dupuis; Stacie B Dusetzina; Cathy Eng; Petra C Feyer; Karin Jordan; Kimberly Noonan; Dee Sparacio; Mark R Somerfield; Gary H Lyman
Journal:  J Clin Oncol       Date:  2017-07-31       Impact factor: 44.544

Review 6.  Anticipatory nausea and vomiting due to chemotherapy.

Authors:  Charles Kamen; Mohamedtaki A Tejani; Kavita Chandwani; Michelle Janelsins; Anita R Peoples; Joseph A Roscoe; Gary R Morrow
Journal:  Eur J Pharmacol       Date:  2013-10-21       Impact factor: 4.432

7.  The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors:  Rudolph M Navari; Cindy K Nagy; Sarah E Gray
Journal:  Support Care Cancer       Date:  2013-01-12       Impact factor: 3.603

Review 8.  Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics.

Authors:  D A Perwitasari; Hans Gelderblom; Jarir Atthobari; Mustofa Mustofa; Iwan Dwiprahasto; Johan W R Nortier; Henk-Jan Guchelaar
Journal:  Int J Clin Pharm       Date:  2011-01-28

Review 9.  Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).

Authors:  Rudolph M Navari
Journal:  Drug Des Devel Ther       Date:  2014-12-17       Impact factor: 4.162

10.  A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Authors:  M Aapro; H Rugo; G Rossi; G Rizzi; M E Borroni; I Bondarenko; T Sarosiek; C Oprean; S Cardona-Huerta; V Lorusso; M Karthaus; L Schwartzberg; S Grunberg
Journal:  Ann Oncol       Date:  2014-03-05       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.